[Abstract]:Accessing this technology expands Viva Biotech's large molecule capabilities by supporting the design and production of bispecific antibodies.
Recently, Viva Biotech (Shanghai) Co., Ltd. ("Viva Biotech") entered into a license agreement with Lonza to obtain access to Lonza's bYlok® bispecific pairing technology. This demonstrates Viva Biotech's drive to improve the production of bispecific antibodies and bring these therapies to clinic.
Lonza's bYlok® technology is an innovative bispecific antibody design solution to overcome the industry-wide challenge of heavy-light chain mispairing. Lonza's bYlok® technology enhances the production efficiency and quality of bispecific antibodies, thereby facilitating the development of these next-generation molecules. Accessing this technology expands Viva Biotech's large molecule capabilities by supporting the design and production of bispecific antibodies.
（Technical Process）
Dr. Xinyu Deng, Vice President of Viva Biotech: “We are delighted to enter into this bYlok® bispecific antibody technology licensing agreement with Lonza. The production of bispecific antibodies can face significant challenges in terms of mispairing and downstream processing. Lonza's bYlok® technology platform effectively addresses these challenges by supporting the design, development and large-scale production of bispecific antibodies, without compromising on cost and time to market. Using Lonza's bYlok® technology is expected to enhance the efficiency and success of our bispecific-related drug development programs.”
